The prognostic value of fibrinogen to albumin ratio in malignant tumor patients: A meta-analysis
BackgroundRecent studies have shown that the fibrinogen to albumin ratio (FAR) is closely related to the prognosis of various cancers. The aim of this systematic review and meta-analysis was to investigate the prognostic value of FAR in malignancies based on the available evidence.MethodTo systemati...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-09-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2022.985377/full |
| _version_ | 1811208445493248000 |
|---|---|
| author | Baibei Li Huachu Deng Biao Lei Leijie Chen Xinyuan Zhang Dingran Sha |
| author_facet | Baibei Li Huachu Deng Biao Lei Leijie Chen Xinyuan Zhang Dingran Sha |
| author_sort | Baibei Li |
| collection | DOAJ |
| description | BackgroundRecent studies have shown that the fibrinogen to albumin ratio (FAR) is closely related to the prognosis of various cancers. The aim of this systematic review and meta-analysis was to investigate the prognostic value of FAR in malignancies based on the available evidence.MethodTo systematically search the Cochrane Library, Embase, PubMed, Google Scholar, Baidu scholars, CNKI and VIP databases for relevant studies published before April 1, 2022, and to evaluate the fibrinogen-to-albumin ratio (FAR) and survival of patients with malignant tumors through a meta-analysis relationship between the results. Results. This meta-analysis included 19 eligible studies involving 5926 cancer patients. We found that high FAR was associated with poor overall survival (HR=2.25, 95%CI 1.86-2.74, p<0.001), recurrence-free survival (HR=2.29, 95%CI 1.91-2.76, P<0.001), progression-free survival (HR: 2.10, 95%CI 1.58-2.79, p<0.001), disease-free survival (HR=1.52, 95%CI 1.17-1.96, p=0.001), and time to recurrence (HR: 1.555, 95%CI 1.031-2.346, P=0.035) was significantly correlated.ConclusionsHigh FAR is significantly associated with poor clinical outcomes in cancer, suggesting that it may be an important predictor of prognosis in patients with malignancies. |
| first_indexed | 2024-04-12T04:21:28Z |
| format | Article |
| id | doaj.art-a4c7809e07f541339b44c6daa5b034a3 |
| institution | Directory Open Access Journal |
| issn | 2234-943X |
| language | English |
| last_indexed | 2024-04-12T04:21:28Z |
| publishDate | 2022-09-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj.art-a4c7809e07f541339b44c6daa5b034a32022-12-22T03:48:13ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2022-09-011210.3389/fonc.2022.985377985377The prognostic value of fibrinogen to albumin ratio in malignant tumor patients: A meta-analysisBaibei Li0Huachu Deng1Biao Lei2Leijie Chen3Xinyuan Zhang4Dingran Sha5Department of Hepatobiliary Surgery, The First Affiliated Hospital of Guangxi Medical University, Nanning, ChinaDepartment of Gastrointestinal Surgery, the First Affiliated Hospital of Guangxi Medical University, Nanning, ChinaDepartment of Hepatobiliary Surgery, The First Affiliated Hospital of Guangxi Medical University, Nanning, ChinaThe First Affiliated Hospital of Guangxi Medical University, Nanning, ChinaThe First Affiliated Hospital of Guangxi Medical University, Nanning, ChinaDepartment of Urology Surgery, The First Affiliated Hospital of Guangxi Medical University, Nanning, ChinaBackgroundRecent studies have shown that the fibrinogen to albumin ratio (FAR) is closely related to the prognosis of various cancers. The aim of this systematic review and meta-analysis was to investigate the prognostic value of FAR in malignancies based on the available evidence.MethodTo systematically search the Cochrane Library, Embase, PubMed, Google Scholar, Baidu scholars, CNKI and VIP databases for relevant studies published before April 1, 2022, and to evaluate the fibrinogen-to-albumin ratio (FAR) and survival of patients with malignant tumors through a meta-analysis relationship between the results. Results. This meta-analysis included 19 eligible studies involving 5926 cancer patients. We found that high FAR was associated with poor overall survival (HR=2.25, 95%CI 1.86-2.74, p<0.001), recurrence-free survival (HR=2.29, 95%CI 1.91-2.76, P<0.001), progression-free survival (HR: 2.10, 95%CI 1.58-2.79, p<0.001), disease-free survival (HR=1.52, 95%CI 1.17-1.96, p=0.001), and time to recurrence (HR: 1.555, 95%CI 1.031-2.346, P=0.035) was significantly correlated.ConclusionsHigh FAR is significantly associated with poor clinical outcomes in cancer, suggesting that it may be an important predictor of prognosis in patients with malignancies.https://www.frontiersin.org/articles/10.3389/fonc.2022.985377/fullfibrinogen to albumin ratioprognosismeta-analysismalignant tumorbiomarker |
| spellingShingle | Baibei Li Huachu Deng Biao Lei Leijie Chen Xinyuan Zhang Dingran Sha The prognostic value of fibrinogen to albumin ratio in malignant tumor patients: A meta-analysis Frontiers in Oncology fibrinogen to albumin ratio prognosis meta-analysis malignant tumor biomarker |
| title | The prognostic value of fibrinogen to albumin ratio in malignant tumor patients: A meta-analysis |
| title_full | The prognostic value of fibrinogen to albumin ratio in malignant tumor patients: A meta-analysis |
| title_fullStr | The prognostic value of fibrinogen to albumin ratio in malignant tumor patients: A meta-analysis |
| title_full_unstemmed | The prognostic value of fibrinogen to albumin ratio in malignant tumor patients: A meta-analysis |
| title_short | The prognostic value of fibrinogen to albumin ratio in malignant tumor patients: A meta-analysis |
| title_sort | prognostic value of fibrinogen to albumin ratio in malignant tumor patients a meta analysis |
| topic | fibrinogen to albumin ratio prognosis meta-analysis malignant tumor biomarker |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2022.985377/full |
| work_keys_str_mv | AT baibeili theprognosticvalueoffibrinogentoalbuminratioinmalignanttumorpatientsametaanalysis AT huachudeng theprognosticvalueoffibrinogentoalbuminratioinmalignanttumorpatientsametaanalysis AT biaolei theprognosticvalueoffibrinogentoalbuminratioinmalignanttumorpatientsametaanalysis AT leijiechen theprognosticvalueoffibrinogentoalbuminratioinmalignanttumorpatientsametaanalysis AT xinyuanzhang theprognosticvalueoffibrinogentoalbuminratioinmalignanttumorpatientsametaanalysis AT dingransha theprognosticvalueoffibrinogentoalbuminratioinmalignanttumorpatientsametaanalysis AT baibeili prognosticvalueoffibrinogentoalbuminratioinmalignanttumorpatientsametaanalysis AT huachudeng prognosticvalueoffibrinogentoalbuminratioinmalignanttumorpatientsametaanalysis AT biaolei prognosticvalueoffibrinogentoalbuminratioinmalignanttumorpatientsametaanalysis AT leijiechen prognosticvalueoffibrinogentoalbuminratioinmalignanttumorpatientsametaanalysis AT xinyuanzhang prognosticvalueoffibrinogentoalbuminratioinmalignanttumorpatientsametaanalysis AT dingransha prognosticvalueoffibrinogentoalbuminratioinmalignanttumorpatientsametaanalysis |